|
|
Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab
Julien Taieb
,
Aziz Zaanan
,
Karine Le Malicot
,
Catherine Julié
,
Hélène Blons
et al.
Article dans une revue
hal-01427989v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial
Thierry André
,
Dewi Vernerey
,
Laurent Mineur
,
Jaafar Bennouna
,
Jérôme Desramé
et al.
Article dans une revue
hal-01951156v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects
Simon Pernot
,
Cecile Badoual
,
Magali Terme
,
Florence Castan
,
Aurelie Cazes
et al.
Article dans une revue
hal-01579145v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9)
Thomas Aparicio
,
Francois Ghiringhelli
,
Valérie Boige
,
Karine Le Malicot
,
Julien Taieb
et al.
Article dans une revue
hal-01728824v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|